Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Anti-CD20-Mediated B Cell Depletion Is Associated with Reduced Osteoclastogenic Signals and Bone Mass Preservation: Clinical Observation in Patients with Follicular Lymphoma Supplemented By Animal Studies in a Murine Model

Albert Kolomansky, MD, Irit Kay, MD, Nathalie Ben-Califa, PhD, Anton Gorodov, BSc, Zamzam Awida, BSc, Ofer Sadovnic, MD, Maria Ibrahim, BSc, Tamar Liron, PhD, Sahar Hiram-Bab, PhD, Howard S. Oster, MD PhD, Nadav Sarid, MD, Chava Perry, MD PhD, Yankel Gabet, DMD, PhD, Moshe Mittelman, MD, Drorit Neumann, PhD

Blood (2020) 136 (Supplement 1): 13.

https://doi.org/10.1182/blood-2020-142295

Published: 2020

Journal Articles

The Risk of Bleeding in Patients Receiving Ibrutinib Combined with Novel Direct Oral Anticoagulants

Michal Ariela Raz, MD, Jon E. Arnason, MD, Osnat Bairey, MD PhD, Lev Shvidel, MD, Ariel Aviv, MD, Sharon Ben Baruch, MD, Chava Perry, MD PhD, Nadav Sarid, MD, David Varon, MD, Ilya Kirgner, MD, Yair Herishanu, MD, Irit Avivi

Blood (2019) 134 (Supplement_1): 4314.

https://doi.org/10.1182/blood-2019-125356

Published: 2019

Journal Articles

Is the Achievement of Pre-Autologous Transplant CR Necessary Indeed in Refractory/ Relapsed DLBCL Patients? a Retrospective Multicenter Study

Liat Shargian-Alon, MD, Hanna Bernstine, Galit Perets, MD, Ronit Gurion, Anat Gafter-Gvili, MD, Oren Pasvolsky, MD, Michal Navon Sela, Chava Perry, MD PhD, Irit Avivi, MD, Odelia Amit, MD, Pia Raanani, MD, Ron Ram, MD, Moshe Yeshurun, MD

Blood (2019) 134 (Supplement_1): 5703.

https://doi.org/10.1182/blood-2019-131229

Published: 2019

Journal Articles

Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data

Yafit Segman, MD, Elena Ribakovsky, MD, Abraham Avigdor, MD, Vladimir Vainstein, MD, Neta Goldschmidt, MD, Shimrit Ringelstein Harlev, MD, Odit Gutwein, Uri Abadi, MD, Anatoly Nemets, MD, Orit Sofer, Najib Dally, MD, Kalman Filanovsky, MD, Merav Leiba, MD, Nadav Sarid, MD, Noam Benyamini, MD, Yair Herishanu, MD, Ron Ram, MD, Chava Perry, MD PhD, Irit Avivi

Blood (2019) 134 (Supplement_1): 5321.

https://doi.org/10.1182/blood-2019-124164

Published: 2019

Journal Articles

Wnt Signaling in Red Blood Cells

Rina Rosin-Arbesfeld, Michal Caspi, Ronen Siman-Tov, Yakir Levi, Chava Perry, MD PhD

Blood (2016) 128 (22): 4806.

https://doi.org/10.1182/blood.V128.22.4806.4806

Published: 2016

Journal Articles

Lymphocyte Activation Gene 3-a Novel Therapeutic Target in Chronic Lymphocytic Leukemia

Mika Shapiro, PhD, Ben-Zion Katz, PhD, Chava Perry, MD PhD, Clare Sun, MD, Nili Dezorella, M.Sc, Sigi Kay, PhD, Irit Avivi, MD, Adrian Wiestner, MD PhD, Herishanu Yair, MD

Blood (2016) 128 (22): 2018.

https://doi.org/10.1182/blood.V128.22.2018.2018

Published: 2016

Journal Articles

Primary Splenic Diffuse Large B-Cell Lymphoma (PS-DLBCL): Splenectomy Improves Survival

Osnat Bairey, MD, Lev Shvidel, MD, Chava Perry, MD PhD, Eldad J Dann, MD, Rosa Ruchlemer, MD, Tamar Tadmor, MD, Neta Goldschmidt, MD

Blood (2014) 124 (21): 4439.

https://doi.org/10.1182/blood.V124.21.4439.4439

Published: 2014

Journal Articles

Absolute Monocyte Count Trichotomizes Chronic Lymphocytic Leukemia Into High Risk Patients With Immune Dysregulation, Disease Progression and Poor Survival

Yair Herishanu, MD, Sigi Kay, PhD, Varda Deutsch, PhD, Jonathan Ben-Ezra, MD, Elizabeth Naparstek, MD, Chava Perry, MD/PhD, Ben-Zion Katz, PhD

Blood (2013) 122 (21): 4724.

https://doi.org/10.1182/blood.V122.21.4724.4724

Published: 2013

Journal Articles

Divergence in CD19-Mediated Signaling Unfolds Intra-Clonal Diversity in Chronic Lymphocytic Leukemia Which Correlates with Disease Progression

Yair Herishanu, MD, Sigi Kay, PhD, Nili Dezorella, MSc, Chava Perry, MD/PhD, Varda Deutsch, PhD, Aaron Polliack, MD, Elizabeth Naparstek, MD, Benzion Katz, PhD

Blood (2012) 120 (21): 4570.

https://doi.org/10.1182/blood.V120.21.4570.4570

Published: 2012

Journal Articles

Increased CD39 Expression on CD4+ T-Lymphocytes Has Clinical and Prognostic Significance in Chronic Lymphocytic Leukemia,

Yair Herishanu, MD, Inbal Hazan-Hallevi, PhD, Sigi Kay, PhD, Varda Deutsch, PhD, Aaron Polliack, MD, Elizabeth Naparstek, MD, Chava Perry, MD/PhD

Blood (2011) 118 (21): 3895.

https://doi.org/10.1182/blood.V118.21.3895.3895

Published: 2011

Journal Articles

Intra-Clonal Diversity Identified by CD19-Mediated Signaling Correlates with Disease Progression In Chronic Lymphocytic Leukemia (CLL)

Yair Herishanu, MD, Sigi Kay, PhD, Nili Dezorella, BSc., Inbal Hazan-Hallevi, PhD, Svetlana Trestman, MD, Chava Perry, MD/PhD, Varda Deutsch Deutsch, PhD, Aaron Polliack, MD, Elizabeth Naparstek, MD, Ben-Zion Katz, PhD

Blood (2010) 116 (21): 3577.

https://doi.org/10.1182/blood.V116.21.3577.3577

Published: 2010

Journal Articles

Cholinergic Stress Responses Facilitate the Molecular Mechanisms Underlying Granulocytosis.

Varda R. Deutsch, PhD, Marjorie Pick, MSc, Dan Grisaru, MD, PhD, Chava Perry, MD, Elizabeth Naparstek, MD, Tzvee Lapidot, PhD, Hermona Soreq, PhD

Blood (2004) 104 (11): 1467.

https://doi.org/10.1182/blood.V104.11.1467.1467

Published: 2004

NARROW

Anti-CD20-Mediated B Cell Depletion Is Associated with Reduced Osteoclastogenic Signals and Bone Mass Preservation: Clinical Observation in Patients with Follicular Lymphoma Supplemented By Animal Studies in a Murine Model

The Risk of Bleeding in Patients Receiving Ibrutinib Combined with Novel Direct Oral Anticoagulants

Is the Achievement of Pre-Autologous Transplant CR Necessary Indeed in Refractory/ Relapsed DLBCL Patients? a Retrospective Multicenter Study

Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data

Wnt Signaling in Red Blood Cells

Lymphocyte Activation Gene 3-a Novel Therapeutic Target in Chronic Lymphocytic Leukemia

Primary Splenic Diffuse Large B-Cell Lymphoma (PS-DLBCL): Splenectomy Improves Survival

Absolute Monocyte Count Trichotomizes Chronic Lymphocytic Leukemia Into High Risk Patients With Immune Dysregulation, Disease Progression and Poor Survival

Divergence in CD19-Mediated Signaling Unfolds Intra-Clonal Diversity in Chronic Lymphocytic Leukemia Which Correlates with Disease Progression

Increased CD39 Expression on CD4+ T-Lymphocytes Has Clinical and Prognostic Significance in Chronic Lymphocytic Leukemia,

Intra-Clonal Diversity Identified by CD19-Mediated Signaling Correlates with Disease Progression In Chronic Lymphocytic Leukemia (CLL)

Cholinergic Stress Responses Facilitate the Molecular Mechanisms Underlying Granulocytosis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only